Sirolimus-eluting versus uncoated stents in acute myocardial infarction

Christian Spaulding, Patrick Henry, Emmanuel Teiger, Kevin Beatt, Ezio Bramucci, Didier Carrié, Michel S. Slama, Bela Merkely, Andrejs Erglis, Massimo Margheri, Olivier Varenne, Ana Cebrian, Hans Peter Stoll, David B. Snead, Christoph Bode

Research output: Contribution to journalArticle

537 Citations (Scopus)

Abstract

BACKGROUND: Sirolimus-eluting stents reduce rates of restenosis and reintervention, as compared with uncoated stents. Data are limited regarding the safety and efficacy of such stents in primary percutaneous coronary intervention (PCI) for acute myocardial infarction with ST-segment elevation. METHODS: We performed a single-blind, multicenter, prospectively randomized trial to compare sirolimus-eluting stents with uncoated stents in primary PCI for acute myocardial infarction with ST-segment elevation. The trial included 712 patients at 48 medical centers. The primary end point was target-vessel failure at 1 year after the procedure, defined as target-vessel-related death, recurrent myocardial infarction, or target-vessel revascularization. A follow-up angiographic substudy was performed at 8 months among 174 patients from selected centers. RESULTS: The rate of the primary end point was significantly lower in the sirolimus-stent group than in the uncoated-stent group (7.3% vs. 14.3%, P = 0.004). This reduction was driven by a decrease in the rate of target-vessel revascularization (5.6% and 13.4%, respectively; P

Original languageEnglish
Pages (from-to)1093-1104
Number of pages12
JournalNew England Journal of Medicine
Volume355
Issue number11
DOIs
Publication statusPublished - Sep 14 2006

Fingerprint

Sirolimus
Stents
Myocardial Infarction
Percutaneous Coronary Intervention
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Spaulding, C., Henry, P., Teiger, E., Beatt, K., Bramucci, E., Carrié, D., ... Bode, C. (2006). Sirolimus-eluting versus uncoated stents in acute myocardial infarction. New England Journal of Medicine, 355(11), 1093-1104. https://doi.org/10.1056/NEJMoa062006

Sirolimus-eluting versus uncoated stents in acute myocardial infarction. / Spaulding, Christian; Henry, Patrick; Teiger, Emmanuel; Beatt, Kevin; Bramucci, Ezio; Carrié, Didier; Slama, Michel S.; Merkely, Bela; Erglis, Andrejs; Margheri, Massimo; Varenne, Olivier; Cebrian, Ana; Stoll, Hans Peter; Snead, David B.; Bode, Christoph.

In: New England Journal of Medicine, Vol. 355, No. 11, 14.09.2006, p. 1093-1104.

Research output: Contribution to journalArticle

Spaulding, C, Henry, P, Teiger, E, Beatt, K, Bramucci, E, Carrié, D, Slama, MS, Merkely, B, Erglis, A, Margheri, M, Varenne, O, Cebrian, A, Stoll, HP, Snead, DB & Bode, C 2006, 'Sirolimus-eluting versus uncoated stents in acute myocardial infarction', New England Journal of Medicine, vol. 355, no. 11, pp. 1093-1104. https://doi.org/10.1056/NEJMoa062006
Spaulding, Christian ; Henry, Patrick ; Teiger, Emmanuel ; Beatt, Kevin ; Bramucci, Ezio ; Carrié, Didier ; Slama, Michel S. ; Merkely, Bela ; Erglis, Andrejs ; Margheri, Massimo ; Varenne, Olivier ; Cebrian, Ana ; Stoll, Hans Peter ; Snead, David B. ; Bode, Christoph. / Sirolimus-eluting versus uncoated stents in acute myocardial infarction. In: New England Journal of Medicine. 2006 ; Vol. 355, No. 11. pp. 1093-1104.
@article{9c21494117a54837a1d70ab204238e72,
title = "Sirolimus-eluting versus uncoated stents in acute myocardial infarction",
abstract = "BACKGROUND: Sirolimus-eluting stents reduce rates of restenosis and reintervention, as compared with uncoated stents. Data are limited regarding the safety and efficacy of such stents in primary percutaneous coronary intervention (PCI) for acute myocardial infarction with ST-segment elevation. METHODS: We performed a single-blind, multicenter, prospectively randomized trial to compare sirolimus-eluting stents with uncoated stents in primary PCI for acute myocardial infarction with ST-segment elevation. The trial included 712 patients at 48 medical centers. The primary end point was target-vessel failure at 1 year after the procedure, defined as target-vessel-related death, recurrent myocardial infarction, or target-vessel revascularization. A follow-up angiographic substudy was performed at 8 months among 174 patients from selected centers. RESULTS: The rate of the primary end point was significantly lower in the sirolimus-stent group than in the uncoated-stent group (7.3{\%} vs. 14.3{\%}, P = 0.004). This reduction was driven by a decrease in the rate of target-vessel revascularization (5.6{\%} and 13.4{\%}, respectively; P",
author = "Christian Spaulding and Patrick Henry and Emmanuel Teiger and Kevin Beatt and Ezio Bramucci and Didier Carri{\'e} and Slama, {Michel S.} and Bela Merkely and Andrejs Erglis and Massimo Margheri and Olivier Varenne and Ana Cebrian and Stoll, {Hans Peter} and Snead, {David B.} and Christoph Bode",
year = "2006",
month = "9",
day = "14",
doi = "10.1056/NEJMoa062006",
language = "English",
volume = "355",
pages = "1093--1104",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "11",

}

TY - JOUR

T1 - Sirolimus-eluting versus uncoated stents in acute myocardial infarction

AU - Spaulding, Christian

AU - Henry, Patrick

AU - Teiger, Emmanuel

AU - Beatt, Kevin

AU - Bramucci, Ezio

AU - Carrié, Didier

AU - Slama, Michel S.

AU - Merkely, Bela

AU - Erglis, Andrejs

AU - Margheri, Massimo

AU - Varenne, Olivier

AU - Cebrian, Ana

AU - Stoll, Hans Peter

AU - Snead, David B.

AU - Bode, Christoph

PY - 2006/9/14

Y1 - 2006/9/14

N2 - BACKGROUND: Sirolimus-eluting stents reduce rates of restenosis and reintervention, as compared with uncoated stents. Data are limited regarding the safety and efficacy of such stents in primary percutaneous coronary intervention (PCI) for acute myocardial infarction with ST-segment elevation. METHODS: We performed a single-blind, multicenter, prospectively randomized trial to compare sirolimus-eluting stents with uncoated stents in primary PCI for acute myocardial infarction with ST-segment elevation. The trial included 712 patients at 48 medical centers. The primary end point was target-vessel failure at 1 year after the procedure, defined as target-vessel-related death, recurrent myocardial infarction, or target-vessel revascularization. A follow-up angiographic substudy was performed at 8 months among 174 patients from selected centers. RESULTS: The rate of the primary end point was significantly lower in the sirolimus-stent group than in the uncoated-stent group (7.3% vs. 14.3%, P = 0.004). This reduction was driven by a decrease in the rate of target-vessel revascularization (5.6% and 13.4%, respectively; P

AB - BACKGROUND: Sirolimus-eluting stents reduce rates of restenosis and reintervention, as compared with uncoated stents. Data are limited regarding the safety and efficacy of such stents in primary percutaneous coronary intervention (PCI) for acute myocardial infarction with ST-segment elevation. METHODS: We performed a single-blind, multicenter, prospectively randomized trial to compare sirolimus-eluting stents with uncoated stents in primary PCI for acute myocardial infarction with ST-segment elevation. The trial included 712 patients at 48 medical centers. The primary end point was target-vessel failure at 1 year after the procedure, defined as target-vessel-related death, recurrent myocardial infarction, or target-vessel revascularization. A follow-up angiographic substudy was performed at 8 months among 174 patients from selected centers. RESULTS: The rate of the primary end point was significantly lower in the sirolimus-stent group than in the uncoated-stent group (7.3% vs. 14.3%, P = 0.004). This reduction was driven by a decrease in the rate of target-vessel revascularization (5.6% and 13.4%, respectively; P

UR - http://www.scopus.com/inward/record.url?scp=33748702281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748702281&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa062006

DO - 10.1056/NEJMoa062006

M3 - Article

C2 - 16971716

AN - SCOPUS:33748702281

VL - 355

SP - 1093

EP - 1104

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 11

ER -